Search results
Showing 931 to 945 of 2183 results for guidelines
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190
This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Read biographies for all members of NICE's indicator advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Cardiovascular disease prevention: risk assessment (general population) (IND269)
This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes